"C-Trelin proven effective for SCD treatment¡¦reimb needed"
By Lee, Seok-Jun | translator Hong, Ji Yeon
25.01.22 05:02:37
°¡³ª´Ù¶ó
0
The efficacy¡¤safety of C-Trelin Orally Disintegrated Tab were demonstrated in the large-scale Phase 4 clinical trial, which enrolled 160 study participants
This drug has been a non-reimbursable drug since its approval in 2015¡¦Based on Phase 4 trial results, HLB Pharma is reapplying for reimbursement
¡ãProduct photo of
There is currently no standard therapy available for 'spinocerebellar degeneration (SCD).' Doctors write prescriptions based on a patient's condition, but there are still unmet needs in 'SCD treatment.' Patients affected by disease likewise.SCD is a degenerative disease affecting the cerebellum or spinal cord due to various underlying causes. Ataxia and dysarthria commonly occur at an early stage, but the disease progression accompanies complications, including dysfunction of the heart, lungs, spine, and bones, causing the risk of death.
Other diseases have specific medications; for instance, 'Levodopa' is used for Parkinson's disease and 'aspirin' is used for cerebral thrombosis. Howeve
Lee, Seok-Jun(wiviwivi@dailypharm.com)
If you want to see the full article, please JOIN US (click)